Cervical screening in England and Wales: An update

Current Opinion in Obstetrics and Gynecology

Volumn 16, Issue 6, 2004, Pages 491-496

  Mohan, Shruti ^a   Ind, Thomas ^b  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Cervical cancer screening; Human papillomavirus testing; Liquid based cytology

Indexed keywords

VIRUS VACCINE;

AGE; ANXIETY; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; COLPOSCOPY; COST EFFECTIVENESS ANALYSIS; HUMAN; MALIGNANT TRANSFORMATION; MORBIDITY; PAPANICOLAOU TEST; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; UNITED KINGDOM; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; WART VIRUS; ACTIVE IMMUNIZATION; ADULT; AGED; CYTOLOGY; FEMALE; ISOLATION AND PURIFICATION; MASS SCREENING; METHODOLOGY; MIDDLE AGED; PAPILLOMA VIRUS; UTERINE CERVIX TUMOR; VAGINA SMEAR;

ADULT; AGE FACTORS; AGED; CYTOLOGICAL TECHNIQUES; ENGLAND; FEMALE; HUMANS; IMMUNOTHERAPY, ACTIVE; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; WALES;

EID: 16644364899     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-200412000-00010     Document Type: Review

References (35)

1. Sasieni P, Cuzick J, Farmery E. Accelerated decline in cervical cancer mortality in England and Wales. Lancet 1995; 346:1566-1567.
2. Peto J, Gilham C, Fletcher O, et al. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004; 364:224-226. An investigation into the effects of cervical cancer screening, based on mortality trends prior to the introduction of the programme.
3. Health Statistics Quarterly, summer 2003. London: Office for National Statistics. http://www.statistics.gov.uk/products/p6725.asp
4. Colposcopy and Programme Management. NHS Cervical Screening Programme publication no. 20, Luesley D, Leeson S, editors; April 2004. The most recent NHSCSP guidelines, giving a comprehensive overview of the programme and the alterations which have been made.
5. UK Government Statistical Service Cervical Screening Programme, England: 2002-2003 Bulletin; October 2003.
6. Sasieni P, Adams J, Cuzick J. Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer 2003; 89:88-93. A case-control study comparing screening histories of women with and without invasive cervical cancer. It considers the effect of different screening intervals in different age groups and was largely the basis of new age-related NHSCSP guidelines.
7. Van Winjngaarden W, Duncan ID. Rationale for stopping cervical screening in women over 50. BMJ 1993; 306:967-971.
8. Raffle AE. Cervical screening [editorial]. BMJ 2004; 328:1272-1273. Incisive editorial response to recent NHSCSP guidelines on the screening interval and eligible age range. The resource implications are highlighted.
9. Flannelly G, Monaghan J, Cruickshank M, et al. Cervical screening in women over the age of 50: results of a population based multicentre study. BJOG 2004; 111:362-370. A large population-based study investigating the risk of dyskaryosis in women over 50, according to previous smear history.
10. Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolau test in screening for and follow-up of cervical cytological abnormalities: a systematic review. Ann Intern Med 2000; 132:810-819.
11. Moseley RP, Paget S. Liquid-based cytology: is this the way forward for cervical screening? Cytopathology 2002; 13:71-82.
12. American College of Obstetricians and Gynecologists. Federal study shows conventional Pap test remains most effective way to diagnose cervical cancer. Washington, DC: ACOG Today; 1999.
13. Guidance on the use of liquid based cytology for cervical screening. National Institute for Clinical Excellence (NICE), Technology Appraisal Guidance 69; October 2003. http://www.nice.org.uk. [Accessed August 2004] NICE appraisal of LBC, including metaanalysis of pilot studies and recommendations for its use.
14. Cuzick J, Terry G, Ho L, et al. Association between high-risk HPV types, HLADRB1 and DQB1 alleles and cervical cancer in British Women. Br J Cancer 2000; 82:1348-1352.
15. Cuzick J, Sasieni P, Davies P, et al. A systematic review of the role of HPV testing in the cervical screening programme. Health Technology Assessment; 1999.
16. Morin C, Barati I, Bouchard C, et al. Managing atypical squamous cells of undetermined significance in Papanicolaou smears. J Reprod Med 2001; 46:799-805.
17. Paraskevaidis E, Koliopoulos G, Alamonos Y, et al. Human papillomavirus testing and the outcome of treatment for cervical intraepithelial neoplasia. Obstet Gynaecol 2002; 98:833-836.
18. Cuzick J, Beverley E, Ho L, et al. HPV testing in primary screening of older women. Br J Cancer 1999; 81:554-558.
19. Shlay JC, Dunn T, Byers T, et al. Prediction of cervical intraepithelial neoplasia grade 2-3 using risk assessment and human papillomavirus testing in women with atypia on papanicolaou smears. Obstet Gynecol 2000; 96:410-416.
20. Donnecker C, Siebert U, Thaler CJ. Primary cervical cancer screening by self-sampling of human papillomavirus DNA in internal medicine outpatient clinics. Ann Oncol 2004; 15:863-869. Interesting prospective study of the usefulness and safety of self-testing for HPV as a primary screening tool.
21. Cuzick J, Sasieni P, Davies P, et al. A systematic review of the role of HPV testing within a cervical screening programme: summary and conclusions. Br J Cancer 2000; 83:561-565.
22. Goldie SJ, Kim JJ. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol 2004; 103:619-631. This paper uses mathematical models to evaluate the cost-effectiveness of different screening strategies.
23. PRISMATIC Project Management Team. Assessment of automated primary screening on PAPNET of cervical smears in the PRISMATIC trial. Lancet 1999; 353:1381-1385.
24. Yoshida T, Fukuda T, Sano T, et al. Usefulness of liquid-based cytology specimens for the immunocytochemical study of p16 expression and human papillomavirus testing: a comparative study using simultaneously sampled histology materials. Cancer 2004; 102:100-108. A prospective study comparing immunohistochemical detection of p16 with cytology and HPV status as screening techniques.
25. Chil A, Sikorski M, Bobek M, et al. Alterations in the expression of selected MHC antigens in premalignant lesions and squamous carcinomas of the uterine cervix. Acta Obstet Gynecol Scand 2003; 82:1146-1152.
26. University of Zimbabwe/JHPIEGO Cervical Cancer Project. Visual inspection with acetic acid for cervical cancer screening: test qualities in a primary care setting. Lancet 1999; 53:869-873.
27. Soutter WP, Fletcher A. Invasive cancer of the cervix in women with mild dyskaryosis followed up cytologically. BMJ 1994; 308:1421-1423.
28. Flannelly G, Anderson D, Kitchener HC, et al. Management of women with mild and moderate cervical dyskaryosis. BMJ 1994; 308:1399-1403.
29. Johnson N, Sutton J, Thornton JG, et al. Decision analysis for best management of mildly dyskaryotic smear. Lancet 1993; 343:91-96.
30. Freeman-Wang T, Walker P, Linehan J, et al. Anxiety levels in women attending colposcopy clinics for treatment for cervical intraepithelial neoplasia: a randomised trial of written and video information. BJOG 2001; 108:482-484.
31. Anhang R, Wright TC, Smock L. Women's desired information about human papillomavirus. Cancer 2004; 100:315-320. A paper exploring women's perceptions of HPV and the explanations required to reduce anxiety associated with testing.
32. Marteau TM. Reducing anxiety in women referred for colposcopy using an information booklet. Br J Health Psychol 1996; 1:181-189.
33. Maissie E, Marteau TM, Hankins M, et al. Psychological impact of HPV testing in women with borderline or mildly dyskaryotic cervical smear test results: cross sectional questionnaire study. BMJ 2004; 328:1293. A study focusing on the risks of testing women for HPV whilst they may not fully understand the implications of the infection.
34. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347:1645-1651.
35. Fiander A. Human papillomavirus vaccines. TOG 2004; 6:98-103. An excellent review of the immunological basis and clinical potential of HPV vaccines. The current state of clinical trials is discussed.